You are here

VASCULOX, INC.

Company Information
Address
4320 Forest Park Avenue Suite 303
SAINT LOUIS, MO -
United States


http://www.vasculox.com

Information

UEI: N/A

# of Employees: 7


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    Amount: $299,687.00

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 exp ...

    STTRPhase I2013Department of Health and Human Services National Institutes of Health
  2. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    Amount: $1,131,763.00

    DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
  3. Treatment of Transplant Reperfusion with CD47 antibody

    Amount: $1,533,751.00

    DESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgica ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  4. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    Amount: $276,232.00

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  5. Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.

    Amount: $197,711.00

    DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to op ...

    STTRPhase I2009Department of Health and Human Services National Institutes of Health
  6. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

    Amount: $203,191.00

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government